These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3429684)

  • 1. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
    Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
    Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
    Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
    Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
    Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
    Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of carumonam in patients with renal insufficiency.
    Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
    Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.
    Halstenson CE; Guay DR; Opsahl JA; Hirata CA; Olanoff LS; Novak E; Ko H; Cathcart KS; Matzke GR
    Antimicrob Agents Chemother; 1990 Apr; 34(4):519-23. PubMed ID: 2344159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
    Krakamp B; Tanswell P; Vogel H; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):75-8. PubMed ID: 2917593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.